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Abstract Rationale: Serotonin (5-Hydroxytryptamine, 5-
HT) receptors play an important role in perception, affect
regulation and attention. Pharmacological challenge with
the 5-HT2A agonist psilocybin (PY) is useful in studying
the neurobiological basis of cognition and consciousness.
Objective: Investigation of dose-dependent effects of PY
on psycho(patho)logical and physiological parameters.
Methods: Eight subjects received placebo (PL), and 45
(“very low dose, VLD”), 115 (“low dose, LD”), 215
(“medium dose, MD”), and 315 (“high dose, HD”) mg/kg
body weight PY. The “Altered States of Consciousness
Rating Scale” (5D-ASC), the “Frankfurt Attention Inven-
tory” (FAIR), and the “Adjective Mood Rating Scale”
(AMRS) were used to assess the effects of PY on psy-
cho(patho)logical core dimensions, attention, and mood. A
24-h electrocardiogram (EKG) was recorded and blood
pressure was measured. Plasma concentrations of thyroid-
stimulating hormone (TSH), prolactin (PRL), cortisol
(CORT), adrenocorticotropic hormone (ACTH), and stan-
dard clinical chemical parameters were determined. Re-
sults: PY dose dependently increased scores of all 5D-ASC
core dimensions. Only one subject reacted with transient
anxiety to HD PY. Compared with PL, MD and HD PY led
to a 50% reduction of performance in the FAIR test.
“General inactivation”, “emotional excitability”, and
“dreaminess” were the only domains of the AMRS
showing increased scores following MD and HD PY.
The mean arterial blood pressure (MAP) was moderately
elevated only 60 min following administration of HD PY.
Neither EKG nor body temperature was affected by any
dose of PY. TSH, ACTH, and CORT plasma levels were
elevated during peak effects of HD PY, whereas PRL
plasma levels were increased following MD and HD PY.
Conclusion: PY affects core dimensions of altered states of
consciousness and physiological parameters in a dose-de-
pendent manner. Our study provided no cause for concern
that PY is hazardous with respect to somatic health.
Keywords Psilocybin · Dose–effect study ·
Psycho(patho)logy · Neuroendocrinology ·
Cardiovascular effects · Altered states of consciousness
Introduction
The indolealkylamine psilocybin (PY, 4-phosphoryloxy-
N,N-dimethyltryptamine) is the main psychoactive prin-
ciple of hallucinogenic mushrooms such as Psilocybe
cubensis and Psilocybe semilanceata. PY interacts mainly
with serotonergic neurotransmission (5-HT1A, 5-HT2A,
and 5-HT2C receptor subtypes). Equilibrium dissociation
constants (Ki) are 6 nM for the 5-HT2A receptor subtype
and 190 nM for the 5-HT1A subpopulation (McKenna et
al. 1990). PY and its active metabolite psilocin (PI)
have—in contrast to lysergic acid diethylamide (LSD)—
no affinity for dopamine D2 receptors (Creese 1975). In a
receptor-blocking study, we showed that the psychotropic
effects of PY could be blocked completely by pre-
treatment with the 5-HT2A preferential antagonist ke-
tanserin (Vollenweider et al. 1998) suggesting that PY-
induced effects are mediated primarily via activation of 5-
HT2A receptor subtypes. However, some of the psycho-
tropic effects of PY might be due to downstream effects
on other neurotransmitter systems. For example, we
recently demonstrated in a PET study using the D2-
receptor ligand [11C] raclopride that PY increases striatal
dopamine (Vollenweider et al. 1999). The enhanced
dopaminergic activity correlated with derealization/de-
personalisation phenomena and euphoria. Corresponding
functional interactions of central dopaminergic and sero-
tonergic systems have been demonstrated (Kapur and
Remington 1996). The pharmacology of PY is reviewed
in a paper by Passie et al. (2002). Aside from the popular
(illicit) use as a recreational drug (Cuomo et al. 1994;
Lohrer and Albers 1999; Supprian et al. 2001), PY can
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serve as an experimental tool in neurosciences to study
the neurobiological basis of altered states of conscious-
ness (ASC) (Vollenweider et al. 1997; Gouzoulis-
Mayfrank et al. 1998; Vollenweider et al. 1999; Vollen-
weider and Geyer 2001). Recent investigations revealed
that the serotonin (5-HT) receptor system is of basic
importance also in the modulation of cognitive functions
such as memory and attention (Meneses 1998; Buhot et
al. 2000; Ellis and Nathan 2001). Depending on the
context, activation or inhibition of 5-HT2A receptors leads
to an improvement or an impairment of working memory
function (Williams et al. 2002). Hence, the 5-HT2
receptor agonistic mode of action of psilocin (PI, 4-
hydroxy-N,N,-dimethyltryptamine), the first and pharma-
cologically active metabolite of PY (Hasler 1997;
Lindenblatt et al. 1998) makes this “classic” hallucinogen
also an interesting compound to investigate brain mech-
anisms underlying attention. In view of the diverse and
widespread use of PY, its pharmacological and toxico-
logical properties in humans must be closely investigated
in order to estimate the safety of PY.
Our literature review revealed two human studies on
the acute somatic effects of PY from 1959 and 1961
(Isbell 1959; Hollister 1961) and one study published in
1999 by Gouzoulis-Mayfrank et al. (Gouzoulis-Mayfrank
et al. 1999) using a single dose of PY in eight subjects.
Isbell found a clinically irrelevant, although statistically
significant, elevation of systolic blood pressure after
administration of 86 g/kg body weight PY, but not after
114 g/kg. Hollister’s clinical-chemical measures of
serum cholesterol, alkaline phosphatase, cholinesterase,
and aspartatamino-transferase revealed no differences
between baseline blood samples and samples taken 2 h
post-dose. Gouzoulis et al. (Gouzoulis-Mayfrank et al.
1999) found no significant response of cortisol, prolactin,
or growth hormone on administration of a single moderate
dose of PY (200 g/kg). In the same trial, weak elevations
of systolic blood pressure and body temperature were
noted. In a human study by Strassman and Qualls (1994),
intravenous N,N- dimethyltryptamine (DMT), a halluci-
nogenic compound chemically related to PI, dose depen-
dently raised prolactin and cortisol plasma levels.
The primary aim of this study was to explore the
potential dose–response relationship of PY on multiple
levels, encompassing various (neuro-)psychological and
physiological parameters. The second aim was to estimate
the drug safety of PY for further use in human challenge
studies and to appraise possible associated risks.
Materials and methods
Subjects
Eight volunteers (four male and four female; mean age 29.5 years,
range 22–44 years) were recruited from university and hospital staff
by word of mouth and agreed to participate in the study with
written informed consent. Subjects were healthy according to
physical examination, detailed clinical-chemical blood analysis,
and electrocardiogram. All subjects were screened by structured
psychiatric interview based on the DIA-X computerized diagnostic
expert system (Wittchen and Pfister 1997). Personal and family
histories of major psychiatric diseases as well as personal histories
of illicit drug use were employed as exclusion criteria. The
screening procedure was supplemented by standard psychometric
instruments (Freiburg Personality Inventory FPI, Fahrenberg et al.
1984; State Trait Anxiety Inventory, Trait form STAI-X2; Laux et
al. 1981; and Hopkins Symptom Checklist SCL-90, Derogatis et al.
1973). Since the personality trait factors “rigidity” and “emotional
lability” were identified to be predictors of negative experiences
during ASC (Dittrich 1993), scores exceeding two SD from the
mean value of normative data in the respective subscales of the FPI
(i.e., “openness” and “neuroticism”) were used as exclusion
criteria. Apart from sporadic use of cannabis, our subjects had no
or very limited experience with psychoactive drugs. All subjects
were of normal weight (mean body mass index 21.4, range 18.5–
23.5) and all female volunteers had a regular menstrual cycle and
did not receive oral contraceptives.
Substances
PY for neurochemical stimulation was obtained through the Swiss
Federal Office for Public Health, Department of Pharmaceutics and
Narcotics, Bern. PY capsules (1 mg and 5 mg) were prepared at the
Pharmacy of the Cantonal Hospital of Aarau, Switzerland. Quality
control comprised tests for identity, purity and uniformity of
content. PY and lactose placebo were administered in gelatin
capsules of identical appearance.
Study design
The study protocol was approved by the ethics committee of the
University Hospital of Zrich. Administration of PY to healthy
subjects was authorized by the Swiss Federal Office for Public
Health, Department of Pharmaceutics and Narcotics, Bern. Ac-
cording to our within-subject study design, each volunteer received
placebo (PL) and four different doses of PY in random order on five
experimental days at least 2 weeks apart. PY dosages were as
follows: very low dose (VLD) = 45 g/kg body weight; low dose
(LD) = 115 g/kg; medium dose (MD) = 215 g/kg; and high dose
(HD) = 315 g/kg. Our own investigations (Hasler 1997; Hasler et
al. 1997) revealed that identical doses of PY relative to body weight
cause comparable plasma concentration–time profiles of PI. We
therefore preferred to administer doses relative to body weight
rather than absolute amounts of PY. Both volunteers and investi-
gators were blind with respect to the experimental condition. To
minimize confounding effects of circadian rhythms on hormone
levels, drug dosing took place at approximately the same time. In
all female volunteers, the experiments were performed during the
early follicular phase of their menstrual cycles. Experienced
psychiatrists supervised all experiments.
Psychometric scales
Dimensions of ASC
The rating scale 5D-ASC (Dittrich 1998; Dittrich et al. 1999) is a
visual-analogue scale suited to depict alterations in waking con-
sciousness—including changes in mood, perception, experience of
self and environment, and thought disorders—regardless of the
inducing factor(s) (Dittrich 1996, 1998). Score-sums of the respec-
tive items make up the following five dimensions of the 5D-ASC:
“oceanic boundlessness” (OB) measures derealization and deper-
sonalization phenomena associated with positive emotional states
ranging from heightened mood to euphoria. “Anxious ego dissolu-
tion” (AED) subsumes dysphoric mood states such as anxiety and
fearful delusions, arising mainly from ego-disintegration and loss of
self-control phenomena. The 5D-ASC main scale “visionary
restructuralization” (VR) is constructed of items circumscribing
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“elementary hallucinations,” “synesthesia,” “changed meaning of
percept,” “facilitated recollection,” and “facilitated imagination.”
The “auditory alterations” (AA) scale summarizes acoustic phe-
nomena empirically found during ASC, and the dimension “reduc-
tion of vigilance” (RV) depicts states of drowsiness and impairment
of alertness and cognitive performance. The scale “global ASC
score” (G-ASC) is constructed by addition of the scores from the
OB, AED and VR subscales. Our subjects were asked to complete
5D-ASC rating scales 150 min and 300 min after drug administration
and instructed to thereby rate their experience from the intervals 0–
150 min and 150–300 min, respectively. To facilitate comparison of
scales among each other, 5D-ASC data are presented as percentage
values indicating percentage of maximum absolute scores.
Affective states
The adjective mood rating scale (AMRS) (Janke and Debus 1978)
represents a multidimensional psychometric test developed for
repeated measures of mood states. In practice, a list of 60 adjectives
depicting mood states (e.g. “active,” “lost in thought,” “sociable”)
were presented to the subjects 10, 95 and 275 min and 24 h after
drug intake. The volunteers were instructed to choose from four
possible answers (“not at all,” “somewhat,” “quite,” or “strongly”
appropriate) to rate gradually to what extent each adjective
characterizes their actual mood state. The AMRS consists of 15
subscales that can be subsumed interpretatively to seven domains of
affective states: performance-related activity (efficiency-activation
and concentration), general inactivation (inactivation, tiredness and
drowsiness), extroversion-introversion (extroversion plus inverted
scores from the introversion scale), general well being (self-
confidence and heightened mood), emotional excitability (excit-
ability, sensitivity and aggressiveness), anxiety-depressiveness
(anxiety and depressed mood), and dreaminess.
Frankfurt attention inventory
Dose-dependent effects of PY on sustained attention were assessed
140 min after drug administration using the Frankfurt Attention
Inventory (FAIR; Moosbrugger and Oehlschlgel 1996). This paper
and pencil test measuring concentration behavior consists of 640
stimuli with high similarity that have to be discriminated against
each other within 6 min. The FAIR test quantifies aspects of
concentration behavior displayed in four test scores: “marker
value” (MV) expresses comprehension of test instructions, “per-
formance value” (PV) informs on the amount of attentively
processed test items during a defined test period, “quality value”
(QV) depicts the amount of attentively made decisions respective to
the total amount of decisions, and the “continuity value” (CV)
reflects the extent of continuously upheld concentration over the
entire test duration. The FAIR task provides good test–retest
reliability expressed as a Crohnbachs alpha between 0.85 and 0.91.
Physiological measures
Electrocardiogram
Electrocardiograms (EKG) were continuously registered for 24 h
by use of a portable two-channel Holter recorder, model 90205,
supplied by Spacelabs, Burdick. EKG monitoring was started 1 h
before drug application, and the subjects were instructed to stop the
recorder and remove the electrodes the following day. Signal
quality was monitored with a Cardysuny 501X multichannel
electrocardiograph (Fukuda ME, Kogyo, Japan), and data analysis
was performed using a medical computer Model 90104A from
Spacelabs, Burdick. The following EKG standard parameters were
examined: mean, minimum and maximum heart rates (min1),
number of supraventricular and ventricular extrasystoles (n),
maximum S-T elevation (mm and ), maximum S-T depression
(mm and ), and number of pauses (asystoles; n).
Blood pressure and body temperature
Blood pressure was measured using a Riva-Rocci sphygmanometer
(Erka, Switzerland) 30 min before drug intake and at 5, 30, 60, 90,
120, 165 and 210 min. The axillary body temperature was recorded
at the same time points using a Terumo digital clinical thermometer
C2O2.
Blood pressure data expressed as mean arterial pressure (MAP)
values were calculated as follows: MAP (mm Hg) = diastolic blood
pressure + 1/3 (systolic blood pressure  diastolic blood pressure).
Maximum rise of MAP above PL (PL values averaged from 0–
210 min post-drug administration) is indicated as D MAX MAP.
Blood sampling, blood chemistry, and analysis of hormones
Blood samples for quantification of hormones and clinical-chem-
ical parameters were drawn from an indwelling intravenous
catheter into vacutainer tubes 20 min before drug administration
and at 105 min and 300 min. Plasma was separated by centrifu-
gation (15 min at 3000 rpm) immediately after sampling and stored
at 27C until analysis. The following blood parameters were later
determined at the Institute of Clinical Chemistry of the University
Hospital of Zrich: sodium (Na+), potassium (K+), chloride (Cl),
urea (UR), creatinine (CR), lactate dehydrogenase (LDH), gamma
glutamyltransferase (GGT), alkaline phosphatase (AP), aspartate
aminotransferase (ASAT), alanine aminotransferase (ALAT), thy-
roid-stimulating hormone (TSH), prolactin (PRL), cortisol (CORT),
and adrenocorticotropic hormone (ACTH). Besides sampling into
EDTA-containing vacutainer tubes, blood samples for quantifica-
tion of ACTH were additionally stabilized by adding 2000 KIU of
aprotinin (Trasylol). Analytical methods used for quantification of
clinical-chemical parameters and accuracies for the respective
assays were as follows: Kinetic Jaff-reaction (CR; accuracy 1.7%
CV) (Bonini et al. 1992), enzyme-kinetic assays (LDH; CV 2.9%)
(Knedel et al. 1986), GGT (CV 0.4%) (Bonini et al. 1992), ASAT
(CV 3.1%) (Bonini et al. 1992), ALAT (CV 2.4%) (Bonini et al.
1992), and AP (CV 2.5%) (Knedel et al. 1986), ion-selective
potentiometric assays (Na+; CV 0.5%), K+ (CV 1.0%) and Cl (CV
0.8%) (Bonini et al. 1992), electro-chemiluminescence technology
(TSH; CV 3.9%) and CORT (CV 2.8%), chemiluminescence
immunometric methods (ACTH; CV 8.8%) and PRL (CV 9.6%)
(Robinson and Nelson 1983), and urease-GLDH assay (UR; CV
2.6%) (Bonini et al. 1992). Additional standard hematology
analysis, including automated complete blood counts, was per-
formed prior to the first and at the end of the last experimental day.
Statistical analysis
All statistical calculations were performed using the STATISTICA
for windows software, version 6.0. According to the within-subject
design of the study, every subject served as her/his own control in
order to minimize effects of intraindividual variation in physiolog-
ical and psychological test scores. Univariate two-way ANOVAs
with treatment (PL and four doses of PY) and observation time as
repeated measures were used to reveal differences between PL and
drug conditions for all parameters. When significant main effects or
interactions were detected with the ANOVA procedure, post-hoc
pair-wise comparisons were performed using the Tukey HSD tests.
Significance levels of main effects are cited in the text. Probability
values of P<0.05 were considered statistically significant.
Trapezoid calculation of AUC values (“Area under the data–
time curve”) for analysis of blood pressure and body temperature
data was performed in Microsoft Excel 2000, using the equation
AUC 0tð Þ ¼
Xn1
i¼0
tiþ1  ti
2
MAPi þMAPiþ1ð Þ:
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Results
Acute psychological effects of psilocybin
First subjective changes were perceived by the volunteers
usually 20–40 min following administration of PY. Peak
effects were reported after 60–90 min, lasting for another
60–120 min. PY effects then gradually subsided and were
completely worn off at the 6-h point. Already, the
threshold dose of 45 g/kg PY (VLD) was rated clearly
psychoactive by most of our volunteers. Slight drowsiness
and increased sensitivity and intensification of pre-
existing mood states were most prominent effects at this
dosage level. LD, MD and HD PY (115, 215 and 315 g/
kg) dose dependently induced changes in mood states,
sensory perception (including colorful visual illusions,
complex scenic hallucinations and synesthesias), as well
as alterations in perception of time, space, and self.
Typically, the experiences after MD and HD PY were
rated positive, with retrospective statements ranging from
“pleasurable” to “ineffably beautiful.” “Magic” or “phan-
tasmagoric” were terms often used to circumscribe a PY
experience. However, one volunteer (male, 23 years)
reacted with pronounced anxiety to HD PY. He reported a
fearful experience marked by depressed mood and fear of
losing control. Without pharmacological intervention, his
anxiety during the plateau phase of PY action gradually
subsided and the dysphoric reaction was completely
resolved six hours post-drug ingestion.
Dimensions of ASC
Figure 1 shows detailed psychometric data from the 5D-
ASC rating scale regarding four doses of PY compared
with PL condition. As assessed by both rating intervals
(0–150 min and 150–300 min after drug administration),
PY dose dependently increased scores of all 5D-ASC
scales [main effect of drug: OB (F4,28=8.58, P<0.001),
VR (F4,28=7.26, P<0.001), AA (F4,28=2.72, P<0.05), RV
(F4,28=3.07, P<0.05), G-ASC (F4,28=8.85, P<0.001)],
whereas for the dimension “anxious ego dissolution” a
significance level of P<0.05 was just missed [AED
(F4,28=2.39, P<0.07)]. When calculated with mean scores
from our eight subjects, least-squares linear regressions
show excellent linearity between PY dose and scores of
the three core 5D-ASC dimensions (OB, AED, VR) as
well as the Global ASC score G-ABZ. Correlation
coefficients (r) of the linear regression models of the
examined rating interval 0–150 min were 0.98 for OB
(P<0.003), 0.97 for AED (P<0.005), 0.98 for VR
(P<0.004), and 0.99 for G-ABZ (P<0.002), respectively.
Affective states
Table 1 summarizes time- and dose-dependent effects of
PY on affective states, as assessed with the AMRS. A
three-way ANOVA revealed significant AMRS scale 
treatment  time interaction (F72,504=1.68, P<0.001).
Subsequent post-hoc analysis showed significant increas-
Fig. 1 Subjective effects of psilocybin. Percentage scores from the altered states of consciousness rating scale 5D-ASC (mean€SEM,
n=8). Scores indicate percentage of theoretical scale maxima
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es in the AMRS dimensions “general inactivation” (PY
215 g/kg, t0+95 min: P<0.001; PY 315 g/kg, t0+95 min:
P<0.001 and PY 315 g/kg, t0+275 min: P<0.01),
“emotional excitability” (PY 315 g/kg, t0+95 min:
P<0.001) and “dreaminess” (PY 215 g/kg, t0+95 min:
P<0.001; PY 315 g/kg, t0+95 min: P<0.001; PY 315 g/
kg, t0+275 min: P<0.001 and PY 315 g/kg, t0+24 h:
P<0.01), relative to PL. Increased introversion at the peak
of the drug effect (t0+95 min) is reflected by significantly
decreased scores on the AMRS scale “extroversion-
introversion” (PY 215 g/kg: P<0.01 and PY 315 g/
kg: P<0.001).
Frankfurt attention inventory
PY exerted no significant influence on the FAIR scores
MV (F4,28=0.58, P=0.687) and QV (F4,28=1.39, P=0.261).
In contrast, administration of PY led to a significant
decrease in the FAIR scores PV (F4,28=12.28, P<0.00001)
and CV (F4,28=11.23, P<0.00001) as shown in Table 2.
Thereby PV and CV were not significantly influenced by
VLD and LD PY, whereas MD and HD PY decreased the
respective scores to approximately 50% of values ob-
tained under PL condition.
Acute physiological effects of psilocybin
Electrocardiogram
ANOVA calculations revealed no differences in any of
the examined parameters of the Holter-24 h EKG. No
evidence for a PY-induced change of cardiac electro-
physiology was found. In Table 3, all EKG results and F
and P values from the respective statistical calculations
are resumed. In order to compactly display the EKG
results, all data were classed in three intervals: the
baseline interval (“interval 1”; t01 h–t0), the interval of
acute effects of PY (“interval 2”; t0–t0+6 h), and the
interval covering the time from the end of subjective drug
action up to 24 h (“interval 3”; t0+6 h–t0+24 h).
Table 1 Subjective effects of psilocybin. Dose-dependent scores in the seven domains of affective states from the adjective mood rating
scale (AMRS) (mean€SEM, n=8)
Placebo Psilocybin Psilocybin Psilocybin Psilocybin
VLD (45 g/kg) LD (115 g/kg) MD (215 g/kg) HD (315 g/kg)
Rating 1 (baseline)
Performance-related activity 19.1€1.4 19.3€1.0 18.9€1.7 17.4€0.7 16.6€1.4
General inactivation 16.5€1.6 15.0€2.2 16.3€2.3 13.9€1.0 17.6€2.6
Extroversion-introversion 4.4€1.1 4.6€0.9 5.1€1.1 3.5€0.6 3.0€0.9
General well being 20.0€1.7 20.3€1.2 22.6€1.4 19.5€1.9 18.6€2.2
Emotional excitability 15.4€0.7 15.3€0.7 15.6€1.1 16.5€1.0 16.7€1.7
Anxiety-depressiveness 8.3€0.2 9.0€0.8 8.0€0.0 9.0€0.6 9.9€1.1
Dreaminess 6.3€0.8 6.4€0.7 5.9€0.6 6.0€0.5 5.9€0.7
Rating 2 (t0+95 min)
Performance-related activity 17.8€1.2 16.4€0.9 15.1€1.4 14.9€1.2 14.9€1.7
General inactivation 14.6€1.8 18.0€2.5 21.0€2.2 23.5€1.9*** 24.9€2.0***
Extroversion-introversion 5.3€0.7 2.8€1.4 1.9€1.2 0.3€1.7** 1.9€1.4***
General well being 18.6€1.9 20.4€1.5 20.9€1.8 22.4€2.0 22.0€2.5
Emotional excitability 14.9€1.3 15.0€0.9 15.0€0.9 17.8€1.7 20.6€2.2***
Anxiety-depressiveness 9.0€0.7 8.6€0.5 8.7€0.4 8.9€0.4 11.6€2.6
Dreaminess 6.4€0.7 7.3€0.9 7.6€0.7 11.6€1.0*** 10.6€0.8***
Rating 3 (t0+275 min)
Performance-related activity 18.3€1.3 17.8€1.2 16.3€1.0 16.6€0.8 16.0€0.9
General inactivation 13.6€0.7 16.0€2.1 17.0€1.5 17.0€1.7 21.6€2.3**
Extroversion-introversion 4.8€1.0 4.6€0.9 2.7€1.1 2.0€1.4 1.6€1.6
General well being 19.6€1.9 20.1€1.5 21.1€1.6 21.1€1.3 22.6€1.3
Emotional excitability 14.6€0.9 14.9€1.6 15.1€1.1 15.5€1.2 15.7€1.2
Anxiety-depressiveness 8.3€0.3 8.5€0.5 8.6€0.4 8.4€0.4 8.7€0.5
Dreaminess 6.0€0.7 6.4€0.9 6.7€0.8 7.3€0.9 10.6€0.5***
Rating 4 (t0+24 h)
Performance-related activity 19.7€1.1 20.0€1.3 20.6€1.2 18.7€1.1 16.3€1.3
General inactivation 14.0€0.7 14.3€0.9 14.7€0.9 18.4€2.0 18.7€1.4
Extroversion-introversion 5.4€1.0 5.3€0.6 5.3€0.3 3.0€1.1 1.4€1.8
General well being 19.7€1.7 19.8€1.3 21.0€0.9 18.7€1.0 17.9€1.3
Emotional excitability 15.9€1.1 14.8€1.3 15.4€0.9 15.3€1.5 16.4€0.9
Anxiety-depressiveness 9.4€0.7 8.4€0.4 8.9€0.5 9.3€0.7 10.6€1.1
Dreaminess 5.1€0.5 5.1€0.5 5.6€0.7 7.3€1.0 8.4€0.8**
* P<0.05
** P<0.01
*** P<0.001 compared with placebo condition (Tukey HSD post-hoc test)
149
Blood pressure and body temperature
No statistically significant main effect of PY on MAP
(F4,28=1.81, P=0.155), maximum rise of MAP above
averaged PL values (DMAX MAP; F3,21=1.04, P=0.396),
and area under the MAP–time curve (AUC(0–t) MAP;
F4,28=2.43, P=0.071) was found. ANOVA analysis,
however, detected a significant dose  time interaction
(F28,196=2.34, P=0.0004). As depicted in Fig. 2a, b, a
trend of PY to increase blood pressure is apparent.
Subsequent post-hoc tests revealed that blood pressure
(systolic blood pressure and MAP) was significantly
increased only 60 min following administration of HD
PY, relative to PL (P<0.001). Diastolic blood pressure
was significantly elevated (P<0.05) only 90 min follow-
ing intake of HD PY. Time courses of averaged MAP
values following four doses of PY and PL are shown in
Table 2 Effects of psilocybin on sustained attention. Scores from the Frankfurt attention inventory (FAIR; mean€SEM, n=8)
Placebo Psilocybin Psilocybin Psilocybin Psilocybin
VLD (45 g/kg) LD (115 g/kg) MD (215 g/kg) HD (315 g/kg)
Rating at 140 min post-drug ingestion
Marker value (MV) 0.991€0.003 0.991€0.003 0.993€0.003 0.984€0.009 0.987€0.002
Performance value (PV) 480.6€33.4 456.5€25.8 455.8€31.9 260.7€25.0 *** 258.0€42.0 ***
Quality value (QV) 0.943€0.014 0.959€0.014 0.961€0.004 0.927€0.029 0.910€0.025
Continuity value (CV) 455.9€34.4 438.9€28.0 439.4€32.3 242.6€27.0 *** 243.6€43.3 ***
*P<0.05
**P<0.01
***P<0.001 compared with placebo condition (Tukey HSD post-hoc test)
Table 3 Electrocardiographic data following placebo and four doses of psilocybin (mean€SEM, n=8)
Placebo Psilocybin Psilocybin Psilocybin Psilocybin Main effect
of drug
Main effect
of drug
VLD
(45 g/kg)
LD
(115 g/kg)
MD
(215 g/kg)
HD
(315 g/kg)
F (4, 28)
values
P values
Interval 1 (baseline; t01 h–t0)
Mean heart rate (min1) 78€5 79€5 75€3 85€6 82€6 0.601 0.665
Minimum heart rate (min1) 57€4 62€3 58€3 60€4 65€4 0.589 0.673
Maximum heart rate (min1) 126€6 120€6 130€5 130€7 112€7 2.280 0.086
Supraventricular extrasystoles (n) 1€1 1€1 1€1 1€1 1€1 2.058 0.114
Ventricular extrasystoles (n) 2€1 1€1 2€2 1€1 1€1 2.492 0.067
Maximum S-T elevation (mm) 1.3€0.4 2.0€0.4 2.5€0.5 1.6€0.3 1.6€0.2 1.570 0.210
Maximum S-T elevation (slope, ) 27€7 45€8 46€5 46€4 37€6 1.230 0.321
Maximum S-T depression (mm) 0.3€0.2 0.1€0.2 0.3€0.3 0.2€0.5 0.0€0.2 0.918 0.467
Maximum S-T depression (slope, ) 10€4 17€6 18€6 18€5 14€4 1.178 0.341
Pauses (n) 0€0 0€0 0€0 0€0 0€0 0.148 0.963
Interval 2 (t0 –t0+6 h)
Mean heart rate (min1) 85€5 82€5 82€5 87€6 84€4
Minimum heart rate (min1) 60€4 62€4 61€2 60€3 63€2
Maximum heart rate (min1) 141€5 128€6 137€8 140€8 131€6
Supraventricular extrasystoles (n) 21€6 7€3 19€9 5€2 4€3
Ventricular extrasystoles (n) 16€7 2€2 5€4 5€3 3€2
Maximum S-T elevation (mm) 1.5€0.4 2.2€0.6 2.6€0.5 1.9€0.3 1.6€0.3
Maximum S-T elevation (slope, ) 35€8 46€8 49€5 50€4 43€7
Maximum S-T depression (mm) 0.0€0.2 0.4€0.3 0.4€0.3 0.4€0.3 0.2€0.1
Maximum S-T depression (slope, ) 8€4 16€6 14€8 20€6 13€4
Pauses (n) 0€0 0€0 0€0 0€0 0€0
Interval 3 (t0+6 h –t0+24 h)
Mean heart rate (min1) 73€3 74€5 70€4 77€5 72€2
Minimum heart rate (min1) 55€3 60€4 53€3 55€2 55€1
Maximum heart rate (min-1) 121€2 115€6 118€2 116€6 111€2
Supraventricular extrasystoles (n) 9€3 11€5 10€3 4€1 8€4
Ventricular extrasystoles (n) 8€3 6€3 6€2 4€2 7€3
Maximum S-T elevation (mm) 1.1€0.3 2.1€0.6 2.0€0.4 1.8€0.3 1.6€0.3
Maximum S-T elevation (slope, ) 25€6 38€7 40€5 40€4 34€5
Maximum S-T depression (mm) 0.2€0.2 0.0€0.2 -0.5€0.5 -0.3€0.5 0.3€0.2
Maximum S-T depression (slope, ) 10€4 16€6 14€6 18€5 14€4
Pauses (n) 1€1 1€1 1€1 1€1 1€1
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Fig. 2a, and systolic and diastolic blood pressure follow-
ing HD PY and PL are depicted in Fig. 2b.
Axillary body temperature was not significantly influ-
enced by any of the applied doses of PY (F4,28=0.94,
P=0.452). ANOVA of the corresponding area under the
data–time curves also did not reveal statistical differences
between the groups. Effects of PY on blood pressure and
body temperature are summarized in Table 4.
Neuroendocrine data
ANOVA of the hormone plasma concentrations revealed
a statistically significant main effect of drug only for PRL
(F4,28=6.41, P=0.0009), whereas significant dose  time
interactions were found for all monitored hormones
(TSH: F8,56=3.95, P=0.0009; PRL: F8,56=4.68, P=
0.0002; ACTH: F8,56=4.23, P=0.0005; and CORT:
F8,56=2.43, P=0.025). Tukey HSD post-hoc pairwise
comparison with corresponding values after PL treatment
revealed significantly elevated plasma levels for all
measured parameters in blood samples collected
105 min following HD PY (TSH following PY 315 g/
kg, P<0.01; PRL following PY 315 g/kg, P<0.001;
ACTH following PY 315 g/kg, P<0.01; and CORT
following PY 315 g/kg, P<0.05). PRL plasma concen-
trations were already increased following MD PY (PRL
following PY 215 g/kg, P<0.01). In the plasma samples
collected 300 min post-drug administration, all hormone
concentrations were back to pre-dose levels. Detailed data
for time- and dose-dependent effects of PY on plasma
levels of hormones are given in Table 5.
Blood chemistry and hemogram
With the exception of two liver enzymes determined in
plasma samples taken 105 min following administration
of HD PY (ASAT and GGT; see beneath), PY did not
elicit statistically significant responses from any of the
analyzed clinical-chemical blood parameters. Mean plas-
ma concentrations of all monitored compounds as well as
F and P values deriving from ANOVA calculations of
main effects of drug are summarized in Table 6. Statis-
tically significant drug  time interactions were found
Fig. 2 a Average mean arterial blood pressure (MAP) following
four doses of psilocybin and placebo, respectively (n=8). b Systolic
and diastolic blood pressures following administration of placebo
and HD psilocybin (mean€SEM, n=8)
Table 4 Effects of psilocybin on blood pressure and body temperature (mean€SEM, n=8)
Placebo Psilocybin Psilocybin Psilocybin Psilocybin
VLD (45 g/kg) LD (115 g/kg) MD (215 g/kg) HD (315 g/kg)
MAP1 93€3.9 97€3.9 101€3.6 100€4.2 101€3.9
D MAX MAP2 – 14€4.4 16€4.7 15€3.9 21€5.3
AUC (0–t) MAP3 21447€883 22199€853 23069€926 22935€983 23158€981
Body temp (C) 36.5€0.1 36.6€0.1 36.4€0.2 36.5€0.1 36.6€0.1
AUC (0–t) temp4 8394€31 8428€16 8370€36 8408€21 8418€28
1 Averaged mean arterial pressure (mmHg; 5–210 min post-drug administration)
2 Maximum rise of MAP above averaged placebo values (mmHg)
3 Area under the MAP–time curve (mmHg  min)
4 Area under the body temperature–time curve (C  min)
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only for the liver enzymes ASAT (F8,56=2.26, P=0.036)
and GGT (F8,56=2.15, P=0.046). Consecutive post-hoc
pairwise comparison revealed significantly elevated con-
centrations of these two parameters in the plasma samples
collected 105 min following administration of HD PY
(ASAT P<0.001; GGT P<0.002), relative to PL.
Comparison of hemograms from blood samples pre-
ceding the first and following the last experimental day
revealed no differences whatsoever in any parameter.
None of the hematological parameters of any subject was
out of normal range.
Discussion
Acute psychological effects of psilocybin
Psilocybin (PY) dose dependently induced important
alterations of perception, affect, ego-functions, and
attention in all subjects. The phenomenological concept
of ego-functions (e.g., ego-identity, ego-vitality, ego-
demarcation, etc.) and their perturbations in the course of
ASC or psychopathology is explained by Scharfetter
(1981). Analysis of the 5D-ASC scores revealed that only
MD and HD PY led to a relevant loosening of ego-
boundaries (OB/AED) and to pronounced changes of
perception (VR). The loosening of the demarcation
between self and environment was generally accompanied
by insight and experienced as “touching” or “unifying
with a higher reality” (OB). In one subject, however, HD
PY transiently led to a disturbance of ego functions that
was experienced with pronounced anxiety (AED). Also,
only MD and HD PY induced intermittent geometric and
complex visual hallucinations, whereas VLD and LD PY
led to illusions in terms of intensification or distortion of
visual perception (VR). PY also amplified or altered
acoustic perception (AA), but no auditory hallucinations
occurred during any of the experiments. All PY-induced
symptoms were worn off completely 6–8 h after drug
administration.
As expressed in scores from the AMRS mood rating
scale, increased general inactivation, introversion, and
dreaminess were seen robustly in all subjects. A statis-
tically significant increase in the AMRS subscale
“dreaminess” was still present in the rating 24 h following
administration of HD PY, presumably representing the
need to reflect and integrate the content of a profound
hallucinogen experience well into the next day. Admin-
istration of both VLD and LD PY induced a mental
condition described by one volunteer as “switching
between the worlds”. In this state, normal waking
consciousness is intermittently pervaded with transient
and unstable drug states in a wavelike pattern, but the
“insightfulness” typically experienced after higher doses
of PY is absent. When distinct hallucinogenic effects
were perceived following the two lower doses, they were
short lasting and only present for about 1–2 h. The effect–
time course following VLD PY supports our previous
findings (Hasler 1997; Hasler et al. 1997), that PY effects
arise and wear off with a certain blood level of PI
(approximately 4–6 ng PI/ ml plasma). This opposes the
alternative hypothesis that PY might initiate secondary
downstream brain mechanisms whose subjective effects
could well outlast the presence of pharmacologically
relevant amounts of the active compound in the blood-
stream. We abstained from monitoring plasma concen-
tration–time profiles of PI, since reliable determination of
this highly unstable phenolic compound requires a
sophisticated and costly analysis technique (Hasler et al.
1997; Lindenblatt et al. 1998).
Interestingly, several subjects could not clearly state in
retrospect on which experimental day they had received
Table 5 Neuroendocrine effects of psilocybin. Dose-dependent plasma concentrations of hormones (mean€SEM, n=8)
Placebo Psilocybin Psilocybin Psilocybin Psilocybin
VLD (45 g/kg) LD (115 g/kg) MD (215 g/kg) HD (315 g/kg)
Sampling 1 (baseline, t020 min)
Thyroid-stimulating hormone (TSH [mU/l]) 1.30€0.15 1.62€0.13 1.54€0.13 1.40€0.16 1.27€0.14
Prolactin (PRL [g/l]) 16.7€5.5 16.0€5.4 14.6€4.3 15.5€5.7 14.8€2.8
Adrenocorticotropic hormone (ACTH [ng/l]) 21€6 17€5 17€4 18€6 12€2
Cortisol (CORT [nmol/l]) 432€59 336€54 378€77 382€50 385€71
Sampling 2 (t0+105 min)
Thyroid-stimulating hormone (TSH [mU/l]) 1.24€0.16 1.41€0.09 1.50€0.13 1.54€0.16 1.66€0.22**
Prolactin (PRL [g/l]) 9.5€2.0 12.8€4.6 14.5€5.3 22.4€7.7** 28.0€7.5***
Adrenocorticotropic hormone (ACTH [ng/l]) 20€5 19€4 25€5 42€14 50€12**
Cortisol (CORT [nmol/l]) 348€50 353€85 443€47 522€82 567€74*
Sampling 3 (t0+300 min)
Thyroid-stimulating hormone (TSH [mU/l]) 1.16€0.15 1.38€0.19 1.15€0.09 1.20€0.13 1.18€0.18
Prolactin (PRL [g/l]) 12.4€2.7 9.0€1.6 9.1€1.7 9.7€2.0 12.9€2.9
Adrenocorticotropic hormone (ACTH [ng/l]) 18€4 15€3 15€2 14€2 15€2
Cortisol (CORT [nmol/l]) 353€54 306€64 289€60 294€57 344€61
* P<0.05
** P<0.01
*** P<0.001 compared with placebo condition (Tukey HSD post-hoc test)
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VLD and LD PY, or MD and HD PY, respectively. The
fact that VLD and LD PY as well as MD and HD PY have
common “qualities” in respect of subjective effects is also
mirrored in the results from the FAIR attention test.
Individual scores for the “performance value” and
“continuity value” were almost identical following VLD
and LD PY, and MD and HD PY, respectively. Following
MD and HD PY, both FAIR scores were reduced to
roughly 50% of the scores reached after PL, VLD, or LD
PY. The strongly impaired performance in the FAIR test
under MD and HD PY is difficult to appraise, since the
obvious reduction of attentional abilities due to 5-HT2A
receptor overstimulation may well be confounded by the
(also drug-induced) lack of motivation to perform well in
this task, as stated by several subjects.
Scores from the 5D-ASC dimension RV indicate that
vigilance is reduced less following HD PY than after MD
PY. We propose that following PY in a dosage of 315 g/
kg body weight, noradrenergic neurotransmission is
significantly stimulated as well, leading to an overcom-
pensation of the more inactivating effects of predomi-
nantly 5-HT stimulation induced by lower PY doses. This
reasoning is in line with the hypothesis that hallucinogen-
induced inhibition of Raphe neurons leads to an increased
activity of adjacent noradrenergic neurons of the locus
coeruleus (Marek and Aghajanian 1998; Aghajanian and
Marek 1999).
Table 6 Plasma concentrations of clinical chemical parameters following administration of four doses of psilocybin (mean€SEM, n=8)
Placebo Psilocybin Psilocybin Psilocybin Psilocybin Main effect
of drug
Main effect
of drug
VLD
(45 g/kg)
LD
(115 g/kg)
MD
(215 g/kg)
HD
(315 g/kg)
F (4, 28)
values
P values
Sampling 1 (baseline, t020 min)
Natrium (Na+ [mmol/l]) 139€2 140€1 141€1 139€2 140€1 0.764 0.558
Potassium (K+ [mmol/l]) 4.0€0.1 3.9€0.1 4.0€0.1 4.0€0.1 4.0€0.1 0.891 0.482
Chloride (Cl [mmol/l]) 109€3 104€3 100€3 102€5 108€3 2.053 0.114
Urea (UR [mmol/l]) 4.2€0.4 5.1€0.6 4.6€0.4 4.6€0.6 4.3€0.3 2.220 0.093
Creatinine (CR [mol/l]) 83€6 87€6 82€4 82€4 83€4 0.732 0.578
Lactate dehydrogenase (LDH [U/l]) 272€13 308€18 295€20 295€21 285€13 2.028 0.118
g-Glutamyltransferase (GGT [U/l]) 13€1 13€1 13€1 13€1 13€2 1.380 0.266
Aspartate aminotransferase
(ASAT [U/l])
16€2 18€1 17€2 18€2 16€1 1.548 0.206
Alanine aminotransferase
(ALAT [U/l])
13€1 14€2 15€2 16€3 13€1 1.490 0.232
Alkaline phosphatase (AP [U/l]) 74€9 75€11 78€11 76€11 71€10 0.347 0.844
Sampling 2 (t0+105 min)
Natrium (Na+ [mmol/l]) 138€3 139€1 140€1 138€3 140€1
Potassium (K+ [mmol/l]) 3.8€0.1 3.8€0.1 4.0€0.1 4.0€0.1 4.0€0.1
Chloride (Cl [mmol/l]) 108€2 103€2 100€1 104€3 107€2
Urea (UR [mmol/l]) 4.0€0.4 4.9€0.6 4.4€0.3 4.2€0.5 4.0€0.3
Creatinine (CR [mol/l]) 79€6 82€4 84€5 78€5 72€3
Lactate dehydrogenase (LDH [U/l]) 265€18 306€17 318€29 329€30 331€20
g-Glutamyltransferase (GGT [U/l]) 13€2 13€1 13€2 14€1 16€3**
Aspartate aminotransferase
(ASAT [U/l])
16€2 18€2 19€2 19€2 24€3***
Alanine aminotransferase
(ALAT [U/l])
13€2 15€1 16€2 16€2 18€3
Alkaline phosphatase (AP [U/l]) 74€9 76€10 78€11 83€12 80€12
Sampling 3 (t0+300 min)
Natrium (Na+ [mmol/l]) 137€3 140€1 140€1 138€3 141€1
Potassium (K+ [mmol/l]) 3.8€0.1 3.8€0.1 3.9€0.1 3.9€0.1 3.8€0.1
Chloride (Cl [mmol/l]) 104€3 104€2 101€2 103€3 109€2
Urea (UR [mmol/l]) 3.7€0.3 4.6€0.6 4.0€0.3 3.9€0.4 3.7€0.3
Creatinine (CR [mol/l]) 76€6 80€4 82€4 78€4 78€3
Lactate dehydrogenase (LDH [U/l]) 271€13 315€11 309€16 317€21 302€13
g-Glutamyltransferase (GGT [U/l]) 12€1 13€1 13€1 14€1 15€2
Aspartate aminotransferase (ASAT
[U/l])
16€2 19€3 19€3 18€2 20€2
Alanine aminotransferase
(ALAT [U/l])
13€2 15€2 16€2 14€2 17€2
Alkaline phosphatase (AP [U/l]) 76€10 79€10 81€12 78€11 77€10
* P<0.05
** P<0.01
*** P<0.001 compared with placebo condition (Tukey HSD post-hoc test)
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Acute physiological effects of psilocybin
Due to its general use for clinical purposes, effects of PY
on blood pressure are mainly presented as MAP values
(Table 4), representing the average blood pressure during
a cardiac cycle. Maximum rises of MAP above averaged
PL MAP values within 210 min following drug admin-
istration were calculated for every dosage level of PY and
labeled DMAXMAP. Corresponding absolute peak MAP
values for every PY dosage level can be calculated by
simple addition of the averaged MAP value following PL
(93 mmHg; Table 4) and the D MAX MAP value of the
respective PY dose. For example, the averaged absolute
peak MAP value after administration of HD PY was
114 mmHg (93 mm MAP for PL plus 21 mm D MAX
MAP for HD). As shown in Fig. 2a, compared with PL,
the MAP is significantly elevated only 60 min following
ingestion of HD PY. Looking only at averaged values, the
short-lasting elevation of blood pressure following HD
PY is no cause for concern, but individual values can be
considered critical. Maximum individual values for
systolic and diastolic blood pressure registered 60 min
following application of HD PY were 180/110 mmHg
(female, 29 years) and 170/120 mmHg (male, 24 years),
respectively. Detailed inspection of the psychometric
scales 5D-ASC and AMRS as well as personal reports
gave no evidence for excessive stress or anxiety at this
time point. By contrast, subject 4 (male, 23 years), who
reported great anxiety, did not have significantly elevated
blood pressure. The increase of MAP during peak effects
of HD PY is not surprising because cardiovascular
regulation is partially mediated by central 5-HT2 and 5-
HT1A receptor activation (Ramage 2001). As a comple-
tion to the “D MAX MAP” parameter describing
momentary and short-lasting blood pressure peaks, com-
parison of “Areas under the MAP–time curve” (AUC(0t)
MAP) allows a quantitative assessment of changes in
blood pressure over the entire duration of PY action.
None of the applied doses of PY led to AUC(0–t) MAP
values different from the AUC(0–t) MAP value calculated
from PL data. Despite the possibility of a short-lasting
moderate elevation of blood pressure, in healthy humans
without pre-existing medical conditions, no cardiovascu-
lar complications must be expected from administration
of PY.
As shown in Table 5, administration of PY led to an
increase of plasma concentrations of all analyzed hor-
mones (TSH, PRL, ACTH, and CORT) in samples
collected 105 min following drug administration, i.e.,
during peak effects of PY. PY-induced changes in plasma
levels of TSH, PRL, ACTH and CORT have not been
previously reported. By the 300-min point, all endocrine
parameters were back to baseline values. Due to a
pronounced variability in plasma levels, statistically
significant differences in plasma concentrations relative
to the PL condition were reached for all hormones only
following HD PY, and for PRL also following MD PY. It
is noteworthy that only PRL levels in plasma samples
taken 105 min post-HD PY (28.0€7.5) were out of the
normal physiological range (3.4–24.1 g/l). Taking into
account that CORT plasma levels follow a circadian
rhythm, it is difficult to distinguish between drug effect
and physiological daily fluctuations. The effect of circa-
dian endocrine fluctuation was controlled to some degree
by starting the experiments at the same time each day. It
is unlikely that increased ACTH and CORT plasma
concentrations following HD PY are an expression of
stress, because no correlation between CORT levels and
scores of the anxiety depicting 5D-ASC subscale AED
(r=0.035) were found. An increase of ACTH and CORT
plasma concentrations as a direct result of 5-HT2 receptor
stimulation is not surprising, because both animal and
human studies suggest that pharmacological stimulation
of 5-HT mechanisms activates the hypothalamo-pituitary-
adrenal (HPA) axis, resulting in a release of ACTH and
corticosteroids into the blood stream (Fuller 1981;
Holmes et al. 1982; Van de Kar et al. 2001). Following
5-HT2 receptor stimulation, hypothalamic neurosecretory
transducer cells liberate corticotropin releasing hormone
(CRH), leading to an increase of ACTH and CORT
plasma concentrations. Our findings are in line with the
results of a study by Gouzoulis-Mayfrank et al. (1999)
comparing psychological and physiological effects of
single moderate doses of d-amphetamine, 3,4-methylene-
dioxyethylamphetamine (MDE) and PY. In their investi-
gation, administration of approximately 200 g/kg PY
also led to a statistically non-significant increase of
CORT plasma concentrations. In contrast, their adminis-
tration of MDE induced a robust increase of CORT
plasma concentrations in all volunteers. These findings
suggest that acute stimulation of 5-HT release (as it is
caused by MDE), is more important for activation of the
HPA-axis than direct agonistic action at the 5-HT2
receptor.
PY-induced increase in 5-HT activity is also reflected
by an elevation of PRL plasma levels following admin-
istration of MD and HD PY. This finding was not
unexpected, because release of PRL from the anterior
pituitary is controlled by inhibitory tuberoinfundibular
dopaminergic neurons and by stimulatory 5-HT mecha-
nisms (Prescott et al. 1984; Van de Kar et al. 1985). That
is, dorsal raphe nucleus 5-HT neurons that project to the
hypothalamus appear to be involved in the secretion of
PRL (Meltzer and Nash 1988).
The finding of a moderate, but statistically significant
increase of TSH plasma levels following administration
of HD PY is difficult to interpret, because functional
relationships between the hypothalamic-pituitary-thyroid
(HPT) axis and 5-HT mechanisms are not well understood
and still controversially discussed (Krulich 1982; Man-
nisto 1983; Duval et al. 1999). Some experimental
findings from animal studies indicate that the central 5-
HT system has an inhibitory influence on TSH secretion
(Mitsuma and Nogimori 1983), whereas others propose
the absence of a significant role for 5-HT in the
physiological release of TSH (O’Malley et al. 1984).
Yet other researchers suggest that 5-HT increases TSH
release into the bloodstream, probably by increasing TRH
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(thyroid-releasing hormone) production or by facilitating
the pituitary TSH response to TRH (Silva and Nunes
1996). Our finding of elevated TSH blood levels follow-
ing 5-HT2 receptor challenge is consistent with the
hypothesis of stimulation of the HPT axis by 5-HT
mechanisms. Neuroendocrinological research studies us-
ing pre-treatment with selective 5-HT receptor agonists
and antagonists might contribute to a better understanding
of this issue.
Statistical analysis of plasma concentrations of a
multitude of clinical chemical markers (Table 6) revealed
that PY has an effect solely on two liver enzymes: ASAT
and GGT. Thereby, only HD PY led to a statistically
significant, although clinically irrelevant, short-term
increase of these enzymes. It is noteworthy that also the
transiently increased ASAT and GGT plasma concentra-
tions were not out of normal physiological ranges [ASAT:
10–31 U/l (female) and 10–34 U/l (male); GGT: 7–32 U/l
(female) and 11–50 U/l (male)]. In blood samples taken
300 min following HD PY, ASAT and GGT values were
back to pre-dose levels and no longer significantly
different from respective concentrations determined under
the PL condition. We interpret the finding of a transient
elevation of ASAT and GGT following HD PY as a sign
of non-specific increase of liver enzyme activity as it is
often seen in “liver sensitive” subjects following admin-
istration of a multitude of drugs (Fried 2000).
We see two methodological limitations for the present
study. First, the moderate number of eight subjects may
lead to some distortion of the results, whereby a putative
bias is expected to be most pronounced for psychological
variables. Parameters with small effect sizes are unlikely
to reach the level of statistical significance and therefore
minor effects, e.g., following lower doses of PY, could
have been missed. Second, one might argue that the
highest dose of PY (315 mg/kg) used in this study is not a
“real” high dose, and some effects of PY would be clearly
apparent only following higher doses of PY. To the best
of our knowledge, no controlled clinical studies in
humans have been conducted using higher doses of PY.
For safety reasons, we decided to not use more PY
because we were not willing to expose our subjects to a
potentially more stressful drug effect at this early stage of
investigations.
Conclusions
Our investigations provided no cause for concern that
administration of PY to healthy subjects is hazardous with
respect to somatic health. However, as our data revealed
tendencies of PY to temporarily increase blood pressure,
we advise subjects suffering from cardiovascular condi-
tions, especially untreated hypertension, to abstain from
using PY or PY-containing mushrooms. Furthermore, our
results indicate that PY-induced ASC are generally well
tolerated and integrated by healthy subjects. However, a
controlled clinical setting is needful, since also mentally
stable personalities may, following ingestion of higher
doses of PY, transiently experience anxiety as a conse-
quence of loosening of ego-boundaries.
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